The North America Peptide CDMO Market was valued at $798.00 Million in 2025 and is projected to reach $2.10 Billion by 2035, growing at a CAGR of 10.1 percent over 2026 to 2035, according to Strategic Revenue Insights. GLP-1 and incretin demand is the largest driver, adding 3.6 percentage points to annual growth, because obesity and diabetes drugs are taken by millions of patients for long periods and each dose needs a measurable quantity of peptide API.
Click here for free sample PDF: https://www.strategicrevenueinsights.com/industry/north-america-peptide-cdmo-market
North America Peptide CDMO Market Key Takeaways
- Market value grows 2.6x, from $798.00 Million in 2025 to $1.29 Billion in 2030 and $2.10 Billion in 2035.
- Commercial manufacturing is the largest service at 41 percent of revenue, followed by clinical manufacturing at 24 percent, process development at 22 percent and analytical services at 13 percent.
- Solid-phase synthesis holds 68 percent of value; hybrid routes grow fastest at 11.7 percent as drug makers pursue longer, more complex molecules.
- Pharma holds 63 percent of revenue, but biotech grows faster at 11.2 percent; metabolic disorders hold 46 percent of demand and grow at 12.1 percent.
- The United States holds 84 percent of the market at $670.32 Million; Mexico grows fastest at 10.9 percent as nearshoring draws pharma work.
What Is Driving Growth
Four drivers add 8.7 percentage points to the growth rate. GLP-1 and incretin demand adds 3.6 points, since making this volume by solid-phase synthesis takes large reactors, large amounts of protected amino acids and many purification steps. Capacity expansion adds 2.2 points as CDMOs in the United States and Canada add solid-phase lines and sites near their customers. The novel peptide pipeline adds 1.7 points and biotech outsourcing adds 1.2 points, as venture backed companies without plants buy process development, clinical supply and analytical work. Raw material and solvent constraints remove 1.1 points and pricing pressure on generics removes 0.8 points.
Segments, Regions and Key Players
Innovative and novel peptides account for 64 percent of spending and grow at 11.0 percent, with generic peptides at 36 percent. By technology, solid-phase synthesis holds 68 percent, hybrid 18 percent and liquid-phase 14 percent. The United States rises from $670.32 Million to $1.72 Billion at 9.9 percent, Canada holds 8 percent and grows at 10.1 percent, and Mexico holds 5 percent and grows at 10.9 percent. North America is larger than Europe at $672.00 Million, although Europe grows slightly faster at 10.4 percent.
Bachem leads with 11.5 percent share, followed by CordenPharma at 9.0 percent, PolyPeptide Group at 8.5 percent, Lonza at 6.5 percent, Cambrex at 5.5 percent, AmbioPharm at 4.5 percent and Piramal Pharma Solutions at 3.5 percent. The seven suppliers hold 49 percent of revenue combined, which marks the market as moderately concentrated.
Frequently Asked Questions
How big is the North America Peptide CDMO Market?
The market was worth $798.00 Million in 2025 and is expected to reach $2.10 Billion by 2035, a 10.1 percent CAGR from 2026 to 2035.
Why is GLP-1 demand so important for peptide CDMOs?
GLP-1 drugs for obesity and diabetes are taken by millions of patients for long periods, and every additional patient adds API volume that needs large solid-phase capacity booked years ahead.
Which country grows fastest?
Mexico grows fastest of the three main countries at 10.9 percent as nearshoring draws pharma work, while the United States remains the market at 84 percent of 2025 revenue.
About Strategic Revenue Insights Inc.
Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd headquartered in London, provides syndicated market research reports, consulting and strategic insights. Contact: sales@strategicrevenueinsights.com | www.strategicrevenueinsights.com